Watch Ticker

BridgeBio Pharma, Inc. Common Stock

Go to BridgeBio Pharma, Inc. Common Stock Website

$49.27

1.52 (3.18%)

Live

Previous Close

$47.75

Day Range

$47.005 - $49.41

Previous Day Range

$47.21 - $48.2

Market Cap

$9.0 billion USD

Day Vol.

2.5 million

Previous Day Vol.

2.5 million

Currency

USD

Primary Exchange

Nasdaq

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disor...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Globe Newswire - KRAS Inhibitors Market Size Clinical Trials Patent Approved Drugs Sales Insight

The global KRAS inhibitors market is experiencing significant growth, with four approved drugs targeting KRAS mutations in cancers like lung, colorectal, and pancreatic. Over 80 drugs are in clinical trials, with promising developments in targeted cancer therapies.

Related tickers: RHHBY, BBIO.

Read Full Article

Vandana Singh - Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Alnylam Pharmaceuticals reported a Q1 2025 earnings beat and affirmed its FY2025 sales guidance. Analysts highlighted the strong launch potential of Amvuttra and limited tariff risk due to the company's U.S.-based manufacturing and IP.

Related tickers: ALNY, BBIO.

Read Full Article

Trending Tickers

Please sign in to view